Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

The incidence of Hodgkin's lymphoma (HL) in Chinese children and adolescents is only 1 / 10 of that in Europe and the United States, which is a "rare" childhood tumor. Due to the "drug shortage

  • 0 views
  • 05 Feb, 2021
  • 3 locations
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

In this studylenalidomide was added in the first-line treatment in the newly diagnosed highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared with the

hodgkin's disease
vincristine
rituximab
cancer
cancer chemotherapy
  • 0 views
  • 23 Jan, 2021
  • 1 location
Combination Chemotherapy Including Cisplatin Ifosfamide Gemcitabine L-asparaginase Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

The PIGLETS regimen was devised to replace the conventional SMILE regimen in management of extranodal NK/T cell lymphoma in our institution. It had been three years since the introduction of

t-cell lymphoma
etoposide
dexamethasone
cancer
  • 2 views
  • 22 Jan, 2021
  • 0 views
  • 23 Jan, 2021
  • 1 location
A Prospective Clinical Study of BTK Inhibitor PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma

  • 0 views
  • 15 Apr, 2021
  • 1 location
PD-1 Antibody Chidamide Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma

refractory peripheral t-cell lymphoma
t-cell lymphoma
chidamide
lenalidomide
measurable disease
  • 1 views
  • 24 Jan, 2021
  • 1 location
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific

  • 0 views
  • 23 Jan, 2021
  • 1 location
PD-1 Antibody Chidamide Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.

  • 1 views
  • 23 Jan, 2021
  • 1 location
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.

  • 0 views
  • 25 Jan, 2021
  • 1 location
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

The primary purpose of this study is to evaluate the post-marketing safety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) under actual conditions of use, and to understand the incidence of adverse events (AEs) (serious and non-serious AEs).

imbruvica
mantle cell lymphoma
chronic lymphocytic leukemia
lymphoma
lymphoid leukemia
  • 40 views
  • 30 Jul, 2021
  • 14 locations